基本信息
浏览量:0
职业迁徙
个人简介
My laboratory has a long-standing interest in elucidating the origins and evolution of human and simian immunodeficiency viruses and in studying HIV/SIV gene function and disease mechanisms from an evolutionary perspective. My group was the first to describe the extensive in vivo genetic variability of HIV-1 (Hahn et al., Science, 1986) and to discover that recombination between highly divergent viruses represents a major driving force of HIV/SIV diversification (Robertson et al., Nature, 1995). We also developed methods for the non-invasive detection of SIV in wild-living apes, which led to the identification of the chimpanzee and gorilla reservoirs of pandemic and non-pandemic HIV-1 (Gao et al., Nature, 1999; Keele et al., Science, 2006; d’Arc et al., PNAS, 2015). This work has recently come full circle with the discovery that a highly divergent SIVcpz Env may be suitable to immunofocus HIV-1 bNab responses to the Env trimer apex (Barbian et al., mBio, 2015; Andrabi et al., Cell Rep, 2019).
Although primate lentiviruses have long been thought to be harmless, long-term natural history studies in Gombe National Park, Tanzania, revealed that SIVcpz, like HIV-1, is pathogenic in its natural chimpanzee host (Keele et al., Nature, 2009). Mortality analyses revealed a 10- to 16-fold increased risk of death for SIVcpz infected chimpanzees, and post-mortem analyses confirmed CD4+ T cell depletion and other histopathological findings consistent with AIDS. We also discovered that the chimpanzee CD4 molecule, in contrast to the human CD4, is highly polymorphic in its D1 domain, resulting in nine distinct CD4 alleles that circulate in wild populations. Importantly, this CD4 diversity not only protects chimpanzees against SIVcpz, but also other SIV strains to which chimpanzees are routinely exposed through their hunting behavior (Bibollet-Ruche et al., PNAS, 2019). More recently, we discovered that CD4 receptor diversity represents an ancient protection mechanism against primate lentiviruses in general. We found that the primate CD4 receptor is under long-term balancing selection and that this diversification has been the result of a co-evolutionary arms race between primate lentiviruses and their hosts (Russell et al., PNAS, in press).
We also studied the origins of human malaria. Of the six Plasmodium species that cause malaria in humans, P. falciparum and P. vivax pose the greatest health risk. Until recently, P. falciparum and a single known chimpanzee parasite, P. reichenowi, were believed to have coevolved with their respective host species, while P. vivax was thought to have emerged in South East Asia following a cross-species transmission of a macaque parasite. Studying wild-living chimpanzees and gorillas, we showed that both of these hypotheses are incorrect, and that instead P. falciparum and P. vivax originated from parasites infecting African apes (Liu et al., Nature, 2009; Sundararaman et al., Nat Commun, 2016; Liu et al., Nat Commun., 2017; Loy et al., PNAS, 2018). We found that P. falciparum evolved following a single host switch of a gorilla parasite, while P. vivax emerged from within a Plasmodium species that infects both chimpanzees and gorillas.
We also characterized HIV-1 transmission at the molecular level, developing a theoretical framework that permits the identification and enumeration of transmitted founder HIV-1 and SIV strains (Keele et al., PNAS, 2008; Keele et al., J. Exp. Med., 2009). For this purpose, we developed single genome amplification (SGA) to derive viral sequences without PCR artifacts (Salazar et al., J Virol, 2008). This approach allowed us to dissect virus/antibody coevolution pathways in subjects who developed broadly cross-reactive neutralizing antibodies (bNabs) (Liao et al., Nature, 2013, Gao et al., Cell, 2014, Bonsignori et al., Sci. Transl. Med., 2017; Wagh et al., Cell Rep, 2019), provided a first understanding of the biological phenotype of transmitted founder viruses (Parrish et al., PNAS, 2013; Iyer et al., PNAS, 2017), and led to the development of a novel SHIV infection model that closely resembles HIV-1 infection of humans (Li et al., PNAS, 2016; Roark et a., Science, 2021). More recent studies revealed that HIV-1 resistance to IFN-I varies markedly over the course of the infection, but is highest during viral rebound following treatment interruption, indicating that IFN-mediated pressures shape the biology of viruses that reactivate in vivo from latency (Gondim et al., Sci. Trans. Med., 2021).
In the future, we will continue to work on emerging infectious diseases and build basic and translational research programs in global health. Current projects involve:
1. Exploiting the antigenic conservation of the Env trimer apex across primate lentiviral lineages for AIDS vaccine design. We will determine whether evolutionarily divergent SIV Envs, when expressed as chimeric simian-human immunodeficiency viruses (SHIVs), mRNA-encoded cell surface expressed gp160 trimers, and/or virus-like particles (VLPs), will elicit V2 apex bNabs in rhesus macaques that cross-react with HIV-1.
2. Improving HIV-1 Env immunogens. We will test the hypothesis that by minimizing distracting glycan hole epitopes, enhancing Env affinity for V2 apex bNAbs and their precursors, increasing epitope diversity coverage, and incorporating B cell lineage designs into our immunogens, we will improve V2 apex bNAb germline engagement and enhance bNab development.
3. Studies of ape Plasmodium infections. Mining publicly available whole genome databases of human and ape Plasmodium parasites, we will elucidate the origin and evolution of human P. malariae.
4. Studies of SIVcpz infection of wild chimpanzees. We are interested in the impact of SIVcpz infection on chimpanzee population dynamics and will continue our natural history studies in Gombe National Park and other sites in Tanzania.
5. Characterizing the viral and host effector mechanisms that govern HIV-1 rebound. We recently discovered that rebounding HIV-1 strains are characterized by extraordinary levels of IFN-I resistance. Going forward, we will determine the kinetics and clinical impact of IFN-I resistance during rebound, define the viral determinants of IFN-I resistance and the host interferon stimulated genes (ISGs) that place pressure on the rebounding virus, and trace the provenance of IFN-I resistant rebound viruses.
6. Characterizing the SARS-CoV-2 neutralizing antibody response. We have isolated neutralizing monoclonal antibodies from memory B cells of COVID survivors and determined their breadth and potency against SARS-CoV-2 variants.
Although primate lentiviruses have long been thought to be harmless, long-term natural history studies in Gombe National Park, Tanzania, revealed that SIVcpz, like HIV-1, is pathogenic in its natural chimpanzee host (Keele et al., Nature, 2009). Mortality analyses revealed a 10- to 16-fold increased risk of death for SIVcpz infected chimpanzees, and post-mortem analyses confirmed CD4+ T cell depletion and other histopathological findings consistent with AIDS. We also discovered that the chimpanzee CD4 molecule, in contrast to the human CD4, is highly polymorphic in its D1 domain, resulting in nine distinct CD4 alleles that circulate in wild populations. Importantly, this CD4 diversity not only protects chimpanzees against SIVcpz, but also other SIV strains to which chimpanzees are routinely exposed through their hunting behavior (Bibollet-Ruche et al., PNAS, 2019). More recently, we discovered that CD4 receptor diversity represents an ancient protection mechanism against primate lentiviruses in general. We found that the primate CD4 receptor is under long-term balancing selection and that this diversification has been the result of a co-evolutionary arms race between primate lentiviruses and their hosts (Russell et al., PNAS, in press).
We also studied the origins of human malaria. Of the six Plasmodium species that cause malaria in humans, P. falciparum and P. vivax pose the greatest health risk. Until recently, P. falciparum and a single known chimpanzee parasite, P. reichenowi, were believed to have coevolved with their respective host species, while P. vivax was thought to have emerged in South East Asia following a cross-species transmission of a macaque parasite. Studying wild-living chimpanzees and gorillas, we showed that both of these hypotheses are incorrect, and that instead P. falciparum and P. vivax originated from parasites infecting African apes (Liu et al., Nature, 2009; Sundararaman et al., Nat Commun, 2016; Liu et al., Nat Commun., 2017; Loy et al., PNAS, 2018). We found that P. falciparum evolved following a single host switch of a gorilla parasite, while P. vivax emerged from within a Plasmodium species that infects both chimpanzees and gorillas.
We also characterized HIV-1 transmission at the molecular level, developing a theoretical framework that permits the identification and enumeration of transmitted founder HIV-1 and SIV strains (Keele et al., PNAS, 2008; Keele et al., J. Exp. Med., 2009). For this purpose, we developed single genome amplification (SGA) to derive viral sequences without PCR artifacts (Salazar et al., J Virol, 2008). This approach allowed us to dissect virus/antibody coevolution pathways in subjects who developed broadly cross-reactive neutralizing antibodies (bNabs) (Liao et al., Nature, 2013, Gao et al., Cell, 2014, Bonsignori et al., Sci. Transl. Med., 2017; Wagh et al., Cell Rep, 2019), provided a first understanding of the biological phenotype of transmitted founder viruses (Parrish et al., PNAS, 2013; Iyer et al., PNAS, 2017), and led to the development of a novel SHIV infection model that closely resembles HIV-1 infection of humans (Li et al., PNAS, 2016; Roark et a., Science, 2021). More recent studies revealed that HIV-1 resistance to IFN-I varies markedly over the course of the infection, but is highest during viral rebound following treatment interruption, indicating that IFN-mediated pressures shape the biology of viruses that reactivate in vivo from latency (Gondim et al., Sci. Trans. Med., 2021).
In the future, we will continue to work on emerging infectious diseases and build basic and translational research programs in global health. Current projects involve:
1. Exploiting the antigenic conservation of the Env trimer apex across primate lentiviral lineages for AIDS vaccine design. We will determine whether evolutionarily divergent SIV Envs, when expressed as chimeric simian-human immunodeficiency viruses (SHIVs), mRNA-encoded cell surface expressed gp160 trimers, and/or virus-like particles (VLPs), will elicit V2 apex bNabs in rhesus macaques that cross-react with HIV-1.
2. Improving HIV-1 Env immunogens. We will test the hypothesis that by minimizing distracting glycan hole epitopes, enhancing Env affinity for V2 apex bNAbs and their precursors, increasing epitope diversity coverage, and incorporating B cell lineage designs into our immunogens, we will improve V2 apex bNAb germline engagement and enhance bNab development.
3. Studies of ape Plasmodium infections. Mining publicly available whole genome databases of human and ape Plasmodium parasites, we will elucidate the origin and evolution of human P. malariae.
4. Studies of SIVcpz infection of wild chimpanzees. We are interested in the impact of SIVcpz infection on chimpanzee population dynamics and will continue our natural history studies in Gombe National Park and other sites in Tanzania.
5. Characterizing the viral and host effector mechanisms that govern HIV-1 rebound. We recently discovered that rebounding HIV-1 strains are characterized by extraordinary levels of IFN-I resistance. Going forward, we will determine the kinetics and clinical impact of IFN-I resistance during rebound, define the viral determinants of IFN-I resistance and the host interferon stimulated genes (ISGs) that place pressure on the rebounding virus, and trace the provenance of IFN-I resistant rebound viruses.
6. Characterizing the SARS-CoV-2 neutralizing antibody response. We have isolated neutralizing monoclonal antibodies from memory B cells of COVID survivors and determined their breadth and potency against SARS-CoV-2 variants.
研究兴趣
论文共 10 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
JOURNAL OF MEDICAL PRIMATOLOGYno. SP5.0 (2018): 337.0-337.0
引用0浏览0引用
0
0
Erica Parrish,Clement Wesley Gnanadurai, Nicholas Parrish,Ulrike Sauermann,Katharina Toepfer, Tina Schultheiss, Steven Bosinger,Guido Silvestri,Beatrice Hahn, Christine Stahl-Hennig,Frank Kirchhoff
引用0浏览0引用
0
0
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn